A Multicenter, Open-label Extension Study to Evaluate the long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients with Acute Intermittent Porphyria who have Completed a previous Clinical Study with ALS-AS1

Project: Other project

Project Details

StatusFinished
Effective start/end date12/28/16 → 4/30/21

Funding

  • Alnylam Pharmaceuticals, Inc: $268,478.80